Dapagliflozin: the outcome of it use as add-on therapy in real-life clinical setting

Dapagliflozin is the first novel SGLT2 inhibitor for treatment of Type 2 diabetes. The aim this study was to evaluate its effectiveness and safety in a real-life clinical setting. We analyze data from four hospitals on patients initiated dapagliflozin. HbA1c, weight daily insulin dosage recorded at baseline 6 months follow-up.229 received At baseline, mean HbA1c 82mmol/mol(186) 102 kg(n=159).The average reduction (n=121) 13mmol/mol whereas weight(n=96) 2kg.A requirement(n=41) by 12 units(13%) compared noted. Nine developed candidiasis, eight UTI, five reported symptoms thirst hypoglycaemia out which were one gliclazide. Ten discontinued(4%) dapagliflozin due side effects. Our results confirm that can be used safely effectively Keywords: Dapagliflozin, real world, SGLT2, Continuous...